{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:25:12Z","timestamp":1790857512105,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ajo.2026.07.035","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:44:44Z","timestamp":1784961884000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial"],"prefix":"10.1016","volume":"291","author":[{"given":"Arjun","family":"Watane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-8098","authenticated-orcid":false,"given":"Andre","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Heier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2026.07.035_bib0001","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.035_bib0002","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2026.07.035_bib0003","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","article-title":"A simplified severity scale for age-related macular degeneration: AREDS report no. 18","volume":"123","author":"Ferris","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.035_bib0004","doi-asserted-by":"crossref","DOI":"10.1109\/JSTQE.2016.2561201","article-title":"Proposed mechanisms of photobiomodulation or low-level light therapy","volume":"22","author":"de Freitas","year":"2016","journal-title":"IEEE J Sel Top Quantum Electron"},{"key":"10.1016\/j.ajo.2026.07.035_bib0005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/IAE.0000000000002632","article-title":"A double-masked, randomized, sham-controlled, single-center study with photobiomodulation for the treatment of dry age-related macular degeneration","volume":"40","author":"Markowitz","year":"2020","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.035_bib0006","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40123-022-00640-6","article-title":"LIGHTSITE II randomized multicenter trial: evaluation of multiwavelength photobiomodulation in non-exudative age-related macular degeneration","volume":"12","author":"Burton","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2026.07.035_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000004822","article-title":"Long-term efficacy and safety of photobiomodulation in dry age-related macular degeneration (LIGHTSITE III: 24-month analysis)","author":"Jaffe","year":"2026","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.035_bib0008","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/IAE.0000000000003980","article-title":"LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda light delivery system","volume":"44","author":"Boyer","year":"2024","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.035_bib0009","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.035_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: explanation and elaboration","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.ajo.2026.07.035_bib0011","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ophtha.2013.01.021","article-title":"Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35","volume":"120","author":"Chew","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.035_bib0012","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0039-6257(02)00457-5","article-title":"Health care economic analyses and value-based medicine","volume":"48","author":"Brown","year":"2003","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2026.07.035_bib0013","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","article-title":"Valuing condition-specific health states using simulation contact lenses","volume":"12","author":"Czoski-Murray","year":"2009","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.035_bib0014","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.035_bib0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration","volume":"218","author":"Brown","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.035_bib0016","unstructured":"Python software foundation. Python Language Reference, version 3.12. https:\/\/www.python.org. Accessed March 2026."},{"issue":"7825","key":"10.1016\/j.ajo.2026.07.035_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.035_bib0018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput Sci Eng"},{"issue":"7","key":"10.1016\/j.ajo.2026.07.035_bib0019","first-page":"608","article-title":"Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis","volume":"24","author":"Hernandez","year":"2018","journal-title":"J Manag Care Spec Pharm"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:55:07Z","timestamp":1790772907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"alternative-id":["S0002939426004149"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.035","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}